- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06264921
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
Study Overview
Status
Conditions
- Small Cell Lung Carcinoma
- Gastric Cancer
- Ovarian Neoplasms
- Ovarian Cancer
- Solid Tumor
- Endometrial Neoplasms
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Advanced Solid Tumor
- Endometrial Cancer
- Small-cell Lung Cancer
- Platinum-resistant Ovarian Cancer
- Ovarian Carcinoma
- Solid Tumor, Adult
- Metastatic Gastric Cancer
- Metastatic Endometrial Cancer
- Advanced Gastric Carcinoma
- Metastatic Gastric Carcinoma
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Advanced Ovarian Carcinoma
- Metastatic Tumor
- Endometrial Diseases
- Progesterone-receptor-positive Breast Cancer
- Hormone Receptor Negative Breast Carcinoma
- Metastatic Ovarian Carcinoma
- Advanced Endometrial Carcinoma
- CCNE1 Amplification
- Metastatic Endometrial Carcinoma
- Platinum-refractory Ovarian Carcinoma
Intervention / Treatment
Detailed Description
This is a Phase 1/1b, first-in-human, open-label, multicenter study of NKT3447 in adults with advanced/ metastatic solid tumors. The study consists of 2 parts, a Dose Escalation phase and a Dose Expansion phase. Eligible patients must have confirmed advanced/metastatic solid tumors (as outlined below) with disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment likely to improve the disease outcome in the judgment of the investigator.
Dose Escalation:
- Ovarian cancer
- Endometrial cancer
- Gastric cancer or gastroesophageal junction cancer
- Small cell lung cancer
- Triple-negative breast cancer (human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor negative)
- Estrogen receptor/progesterone-receptor + human epidermal growth factor receptor 2 negative (HER2-) breast cancer (must have progressed following treatment with a CDK4/6 inhibitor, and not suitable for endocrine therapy)
- Other solid tumors with CCNE1 amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next generation sequencing by local liquid or tissue biopsy.
Dose Expansion:
a. Platinum resistant or refractory ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least 1 platinum containing therapy with cyclin E amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next-generation sequencing by local liquid or tissue biopsy.
The Dose Escalation phase will evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors.
The Dose Expansion phase will evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with CCNE1 amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended RP2D.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sponsor Contact
- Phone Number: 3024155127
- Email: clinicaltrials@nikangtx.com
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Sarah Cannon Research Institute at HealthONE
-
Principal Investigator:
- Gerald Falchook, MD, MS
-
Contact:
- Kelly Mozzetta
-
-
Florida
-
Celebration, Florida, United States, 34747
- Recruiting
- AdventHealth Cancer Institute
-
Contact:
- Heather Osorio
- Email: Heather.Osorio@AdventHealth.com
-
Principal Investigator:
- Karolina Kilowski, DO
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- The Gabrail Pharmacology Phase 1 Research Center
-
Principal Investigator:
- Nashat Y Gabrail, MD
-
Contact:
- Carrie Smith
- Email: csmith@gabrailcancercenter.com
-
-
Texas
-
Austin, Texas, United States, 78758
- Recruiting
- Texas Oncology-Austin Midtown NEXT Oncology
-
Principal Investigator:
- Andrae Vandross, MD
-
Contact:
- Erica Torres
- Phone Number: 210-610-5205
- Email: etorres@nextoncology.com
-
-
Utah
-
West Valley City, Utah, United States, 84119
- Recruiting
- START Mountain Region
-
Contact:
- Marie Asay
- Phone Number: 801-907-4770
- Email: marie.asay@startthecure.com
-
Principal Investigator:
- Justin A Call, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must have confirmed unresectable advanced/metastatic solid tumors (as outlined below) with disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment likely to improve the disease outcome in the judgment of the investigator.
Dose Escalation:
- Ovarian cancer
- Endometrial cancer
- Gastric cancer or gastroesophageal junction cancer
- Small cell lung cancer
- Triple-negative breast cancer (human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor negative)
- Estrogen receptor/progesterone-receptor + human epidermal growth factor receptor 2 negative (HER2-) breast cancer (must have progressed following treatment with a CDK4/6 inhibitor, and not suitable for endocrine therapy)
- Other solid tumors with CCNE1 amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next generation sequencing by local liquid or tissue biopsy.
Dose Expansion:
a. Platinum resistant or refractory ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least 1 platinum containing therapy with cyclin E amplification as determined by fluorescence in situ hybridization, quantitative polymerase chain reaction, or next-generation sequencing by local liquid or tissue biopsy.
- Measurable disease per the RECIST v1.1
- An Eastern Cooperative Oncology Group performance status of 0 to 1
- Able to swallow oral medications.
Exclusion Criteria:
- Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and/or radiotherapy, or chemotherapy.
- History of another malignancy with exceptions
- Visceral crisis, lymphangitic spread, CNS metastasis and/or carcinomatous meningitis
- Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade ≤ 1 severity (per CTCAE)
- Clinically active interstitial lung disease
- History of uveitis, retinopathy or other clinically significant retinal disease
- Has known human immunodeficiency virus (HIV), active hepatitis B or C infection
- Prior CDK2 inhibitor, WEE1 inhibitor, or protein kinase membrane associated tyrosine/threonine 1 inhibitor.
- Major surgery within 2 months or minor surgery within 10 days before the first dose of NKT3447
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation
Dose escalation will assess the safety, efficacy, and PK/PD data of oral dosing NKT3447 at increasing dosage levels to determine the MTD and/or preliminary RDEs.
|
Oral CDK2 inhibitor
|
Experimental: Dose Expansion
Dose expansion will include 2 RDEs selected to determine the preliminary antitumor activity and the RP2D.
|
Oral CDK2 inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Dose Limiting Toxicity (DLT) events
Time Frame: 28 days
|
DLTs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 .0.
|
28 days
|
Objective Response Rate (ORR)
Time Frame: 1 year
|
ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as determined by the Investigator
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 2 years
|
PFS defined as the time from the date the participant started study drug to the date the participant experiences an event of disease progression or death.
|
2 years
|
Overall Survival (OS)
Time Frame: 2 years
|
OS defined as the time from the date the participant started study drug to death for any reason.
|
2 years
|
Number of Participants with Adverse Events
Time Frame: 2 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment.
The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
|
2 years
|
Duration of Response (DOR)
Time Frame: 2 years
|
Duration of overall response is defined as the time from the date of first documented CR or PR, assessed by investigator and based on RECIST v. 1.1, to the documented date of progressive disease (PD) or death, whichever occurred first.
|
2 years
|
Disease control rate
Time Frame: 1 year
|
Disease control rate defined as CR + PR + stable disease [SD]
|
1 year
|
Time to Response (TTR)
Time Frame: 1 year
|
TTR is defined as the time from first dose to the first documented CR or PR which is subsequently confirmed.
|
1 year
|
Maximum observed plasma concentration (Cmax) of NKT3447
Time Frame: 1 month
|
Maximum observed plasma concentration (Cmax) of NKT3447
|
1 month
|
Time to maximum observed plasma concentration of NKT3447 (Tmax)
Time Frame: 1 month
|
Time to maximum observed plasma concentration of NKT3447 (Tmax)
|
1 month
|
Observed trough concentration of NKT3447 (Ctrough)
Time Frame: 88 weeks
|
Observed trough concentration of NKT3447 (Ctrough)
|
88 weeks
|
Area under the plasma concentration-time curve (AUC0-t) of NKT3447
Time Frame: 1 month
|
Area under the plasma concentration-time curve (AUC0-t) of NKT3447
|
1 month
|
Apparent clearance (CL/F)
Time Frame: 1 month
|
Apparent clearance (CL/F)
|
1 month
|
Apparent volume of distribution (V/F)
Time Frame: 1 month
|
Apparent volume of distribution (V/F)
|
1 month
|
Half-life (t1/2)
Time Frame: 1 month
|
Half-life (t1/2)
|
1 month
|
Accumulation ratio (AR)
Time Frame: 1 month
|
Accumulation ratio (AR)
|
1 month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Skin Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Endocrine Gland Neoplasms
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Lung Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Stomach Neoplasms
- Breast Neoplasms
- Carcinoma
- Neoplasm Metastasis
- Ovarian Neoplasms
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
- Carcinoma, Ovarian Epithelial
- Triple Negative Breast Neoplasms
- Uterine Diseases
Other Study ID Numbers
- NKT3447-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Cell Lung Carcinoma
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterNational Institute on Aging (NIA)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Unresectable Lung Non-Small Cell Carcinoma | Advanced Lung Non-Small Cell Carcinoma | Advanced... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCarcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell LungUnited States
-
National Cancer Institute (NCI)TerminatedExtensive Stage Lung Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Imago BioSciences, Inc., a subsidiary of Merck...Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell CarcinomaUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Lung Small Cell CarcinomaUnited States, Canada, Korea, Republic of, Mexico
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States